Metly

Based in the US, Metly specializes in delivering software solutions tailored for Business Development teams in the pharmaceutical sector. Their platform integrates AI and real-world insights to enhance decision-making in licensing and manufacturing. Metly provides software solutions aimed at streamlining business development processes for the pharmaceutical industry. The company was founded to address the need for efficient asset sourcing and decision-making in a complex market.

In July 2025, Metly raised EUR 520,000 in pre-seed funding led by Encomenda Capital Partners, with participation from Ona Capital and Dozen Investments. Metly offers a comprehensive software solution designed specifically for Business Development teams in the pharmaceutical industry. The core product integrates structured data, artificial intelligence, and real-world insights to streamline the process of identifying licensing and manufacturing opportunities. By accessing a database of over 35,000 products and 500 sellers worldwide, users can efficiently source new assets, expand into emerging markets, and optimize their portfolios.

The platform facilitates decision-making by providing analysis of supplier credentials, regulatory pathways, and market availability, all within a single interface. Metly's services cater to various geographical markets, including Europe, Latin America, and the Middle East and North Africa, thereby enabling clients to enhance their visibility and market presence in these regions. The end users of this platform include pharmaceutical companies looking to improve their business development strategies and manufacturers seeking to connect with potential buyers. Metly generates revenue primarily through subscription-based models and partnerships with licensors and manufacturers within the pharmaceutical sector.

Clients utilize the platform to engage with verified sellers or buyers and manage their business communications and offers in one centralized location. Transactions typically involve accessing the software for a fee, which allows clients to leverage tailored recommendations and insights based on their specific portfolio needs and market data. This pricing structure is designed to encourage long-term partnerships and frequent interactions between the business development teams and the users of the software. In July 2025, Metly raised EUR 520,000 in pre-seed funding led by Encomenda Capital Partners.

The company plans to use this funding from July 2025 to scale its AI technology, expand its technical and commercial teams, and accelerate its international growth, particularly in the US and China.